These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. Garin MC; Highland KB; Silver RM; Strange C J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563 [TBL] [Abstract][Full Text] [Related]
9. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis. Kowal-Bielecka O; Delcroix M; Vonk-Noordegraaf A; Hoeper MM; Naeije R Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v39-41. PubMed ID: 18784140 [TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Allanore Y; Borderie D; Meune C; Cabanes L; Weber S; Ekindjian OG; Kahan A Arthritis Rheum; 2003 Dec; 48(12):3503-8. PubMed ID: 14674001 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension: screening and evaluation in scleroderma. York M; Farber HW Curr Opin Rheumatol; 2011 Nov; 23(6):536-44. PubMed ID: 21934501 [TBL] [Abstract][Full Text] [Related]
12. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension. Thakkar V; Nikpour M; Stevens WM; Proudman SM Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576 [TBL] [Abstract][Full Text] [Related]
13. Determinants of morbidity and mortality of systemic sclerosis in Canada. Al-Dhaher FF; Pope JE; Ouimet JM Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension. Connolly MJ; Abdullah S; Ridout DA; Schreiber BE; Haddock JA; Coghlan JG Rheumatology (Oxford); 2017 Dec; 56(12):2197-2203. PubMed ID: 29029203 [TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Vonk MC; Broers B; Heijdra YF; Ton E; Snijder R; van Dijk AP; van Laar JM; Bootsma H; van Hal PT; van den Hoogen FH; van Daele PL Ann Rheum Dis; 2009 Jun; 68(6):961-5. PubMed ID: 18511546 [TBL] [Abstract][Full Text] [Related]
18. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Sobanski V; Launay D; Hachulla E; Humbert M Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964 [TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor signalling: a common pathway in pulmonary arterial hypertension and systemic sclerosis. Hatton N; Frech T; Smith B; Sawitzke A; Scholand MB; Markewitz B Int J Clin Pract Suppl; 2011 Aug; (172):35-43. PubMed ID: 21736678 [TBL] [Abstract][Full Text] [Related]
20. [Heart involvement and pulmonary arterial hypertension in patients with systemic sclerosis]. Cikes N Reumatizam; 2010; 57(2):99-104. PubMed ID: 21875012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]